Imunon (IMNN) CEO Restricted Stock Vesting and Share Adjustments Reported
Rhea-AI Filing Summary
Imunon, Inc. (IMNN) reporting person Stacy Lindborg, President & CEO and director, had 1,667 restricted shares vest on September 6, 2025, resulting in an acquisition of 1,667 common shares at $0 per share. After the vesting, Ms. Lindborg beneficially owned 3,584 shares directly and 234 shares indirectly through a 401(k) plan. The filing notes corporate equity adjustments: a 1-for-15 reverse stock split effective July 25, 2025, and a 15% stock dividend paid August 21, 2025, which adjusted previously reported share amounts. The Form 4 was signed by an attorney-in-fact on September 9, 2025.
Positive
- Executive alignment: Vesting of 1,667 restricted shares converts to common stock, aligning the CEO's interests with shareholders
- Transparent disclosure: Filing notes both the 1-for-15 reverse split and the 15% stock dividend, clarifying adjusted share amounts
Negative
- None.
Insights
TL;DR: Routine executive equity vesting converted restricted stock into common shares; ownership changes reflect corporate equity actions.
The report documents the scheduled vesting of 1,667 restricted shares awarded on September 6, 2024, which vested in full on the first anniversary and converted one-for-one into common stock on September 6, 2025. Post-transaction direct beneficial ownership is 3,584 shares, with an additional 234 shares held indirectly via a 401(k). The filing also discloses a 1-for-15 reverse split and a 15% stock dividend that adjusted historic and outstanding award quantities. This is a standard insider vesting event with no cash consideration and no indication of open-market purchases or sales in this filing.
TL;DR: Vesting aligns executive compensation with time-based retention; disclosures of corporate actions are properly noted.
The Form 4 shows time-based restricted stock fully vested per grant terms, demonstrating enforcement of the one-year cliff vesting schedule. The filing includes clear disclosure of the reverse split and stock dividend adjustments, which is important for accurate reporting of ownership and award sizes. There is no evidence in this filing of unusual timing or related-party transactions; the transaction appears consistent with typical equity compensation practices for senior officers who also serve as directors.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock | 1,667 | $0.00 | -- |
| Exercise | Common Stock | 1,667 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Acquisition of common stock resulting from vesting of 100% of the restricted stock granted to Ms. Lindborg on September 6, 2024. Each restricted stock share represents a contingent right to receive one share of Imunon, Inc.'s common stock. On September 6, 2024, Ms. Lindborg received restricted stock representing 1,667 shares (as adjusted for the reverse stock split) subject to a one-year vesting schedule, vesting 100% on the first anniversary of the grant date. As restricted stock shares vest, the vested shares are automatically converted to vested common stock on a one-for-one basis on the vesting date.
